Evidence map›Paper›PMID 38310566›Full record

ArticleCurrent pharmaceutical design2024

Unveiling the Potential of Serum MiR-483-5p: A Promising Diagnostic and Prognostic Biomarker in OLP and OSCC Patients by

Pouria Soltaninezhad, Fatemeh Arab, Nooshin Mohtasham, Mohammadhossein FakherBaheri, Nima Nikbin Kavishahi, Seyed Hamid Aghaee-Bakhtiari, Reza Zare-Mahmoodabadi, Atessa Pakfetrat, Kiarash Izadi Taban, Farnaz Mohajertehran

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Pouria SoltaninezhadDental Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Fatemeh ArabDepartment of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Nooshin MohtashamOral and Maxillofacial Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammadhossein FakherBaheriDepartment of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Nima Nikbin KavishahiDepartment of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Seyed Hamid Aghaee-BakhtiariDepartment of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Reza Zare-MahmoodabadiDepartment of Oral and Maxillofacial Pathology, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran.
Atessa PakfetratOral and Maxillofacial Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Kiarash Izadi TabanDental Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Farnaz MohajertehranDental Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mashhad University of Medical Sciences · IRShahid Sadoughi University of Medical Sciences and Health Services · IR

Funding

Vice Chancellor for Research, MUMS, Mashhad, Iran 991611
6 · The paper itself

Abstract

backgroundOral squamous cell carcinoma (OSCC) and oral lichen planus (OLP) are two separate conditions affecting the mouth and result in varying clinical outcomes and levels of malignancy. Achieving early diagnosis and effective therapy planning requires the identification of reliable diagnostic biomarkers for these disorders. MicroRNAs (miRNAs) have recently received attention as powerful biomarkers for various illnesses, including cancer. In particular, miR-483-5p is a promising diagnostic and prognostic biomarker in various cancers. Therefore, this study aimed to investigate the role of serum miR-483-5p in the diagnosis and prognosis of OLP and OSCC patients by

methodsGSE23558 and GSE52130 data sets were selected, and differential gene expression analysis was performed using microarray data from GSE52130 and GSE23558. The analysis focused on comparing OLP and OSCC samples with normal samples. The genes intersected through the differential gene expression analysis were then extracted to determine the overlapping genes among the upregulated or downregulated DEGs. The downregulated genes among the DEGs were subsequently imported into the miRWalk database to search for potential target genes of miRNA 483-5p that lacked validation. To gain insight into the biological pathways associated with the DEGs, we conducted pathway analysis utilizing tools, such as Enrichr. Additionally, the cellular components associated with these DEGs were investigated by analyzing the String database. On the other hand, blood serum samples were collected from 35 OSCC patients, 34 OLP patients, and 34 healthy volunteers. The expression level of miR-483-5p was determined using quantitative reverse transcription polymerase chain reaction (RT-qPCR). The Kruskal-Wallis test was utilized to investigate the considerable correlation. Moreover, this study explored the prognostic value of miR-483-5p through its association with clinicopathological parameters in OSCC patients.

resultsThe results showed that serum expression of miR-483-5p was considerably higher in OSCC patients compared to OLP patients and healthy controls (p 0.0001) and that this difference was statistically significant. Furthermore, elevated miR-483-5p expression was associated with tumor size, lymph node metastasis, and stage of tumor nodal metastasis in OSCC patients (p 0.001, p 0.038, and p 0.0001, respectively).

conclusionThis study demonstrates the potential of serum miR-483-5p as a promising diagnostic and prognostic biomarker in OSCC and OLP patients. Its upregulation in OSCC patients and its association with advanced tumor stage and potential metastasis suggest the involvement of miR-483-5p in critical signaling pathways involved in cell proliferation, apoptosis, and cell cycle regulation, making it a reliable indicator of disease progression. Nevertheless, additional experimental studies are essential to validate these findings and establish a foundation for the advancement of targeted therapies and personalized treatment approaches.

Indexed as

Biomarkers, TumorLichen Planus, OralMicroRNAsMouth NeoplasmsCarcinoma, Squamous CellComputer SimulationGene Expression Regulation, NeoplasticHumansPrognosisBiomarkers, TumorMicroRNAsMIRN483 microRNA, humandifferential gene expression.in silico analysismiR-483-5poral lichen planusOral squamous cell carcinomaprognosis

Identifiers

PMID38310566
OpenAlexW4391519303

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.